154 related articles for article (PubMed ID: 23674897)
1. PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma.
Zhang L; Shi L; Zhao X; Wang Y; Yue W
Onco Targets Ther; 2013; 6():497-502. PubMed ID: 23674897
[TBL] [Abstract][Full Text] [Related]
2. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
[TBL] [Abstract][Full Text] [Related]
3. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
[TBL] [Abstract][Full Text] [Related]
4. [PIK3CA gene mutations in Chinese women with HR
Wu SF; Wang XF; Liu YY; Xia C; Liang ZY; Zeng X
Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1246-1250. PubMed ID: 36480834
[No Abstract] [Full Text] [Related]
5. Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients.
Filipenko ML; Os'kina NA; Oskorbin IA; Mishukova OV; Ovchinnikova LK; Gershtein ES; Kushlinskii NE
Bull Exp Biol Med; 2017 Jun; 163(2):250-254. PubMed ID: 28726194
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA mutation status in Japanese lung cancer patients.
Kawano O; Sasaki H; Endo K; Suzuki E; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Lung Cancer; 2006 Nov; 54(2):209-15. PubMed ID: 16930767
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA mutations in breast cancer: A Tunisian series.
Ben Rekaya M; Sassi F; Saied E; Bel Haj Kacem L; Mansouri N; Zarrouk S; Azouz S; Rammeh S
PLoS One; 2023; 18(5):e0285413. PubMed ID: 37195967
[TBL] [Abstract][Full Text] [Related]
8. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
Barbareschi M; Buttitta F; Felicioni L; Cotrupi S; Barassi F; Del Grammastro M; Ferro A; Dalla Palma P; Galligioni E; Marchetti A
Clin Cancer Res; 2007 Oct; 13(20):6064-9. PubMed ID: 17947469
[TBL] [Abstract][Full Text] [Related]
9. Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent
Wu Y; Zhang K; Guan J; Wu W; Zhang J; Chen H
Cancer Manag Res; 2021; 13():7047-7053. PubMed ID: 34526820
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
[TBL] [Abstract][Full Text] [Related]
11. Helical and kinase domain mutations of
Vatte C; Al Amri AM; Cyrus C; Chathoth S; Alsayyah A; Ahmad A; Akhtar MS; Alrashidi NF; Jayaseeli N; Al Wadani H; Al Zahrani A; Al Ali AK
Oncol Lett; 2019 Sep; 18(3):2427-2433. PubMed ID: 31404155
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutations in small bowel adenocarcinoma.
Shenoy S
Tumori; 2015 Jun; 101(3):e85-7. PubMed ID: 25908046
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
Scheffler M; Bos M; Gardizi M; König K; Michels S; Fassunke J; Heydt C; Künstlinger H; Ihle M; Ueckeroth F; Albus K; Serke M; Gerigk U; Schulte W; Töpelt K; Nogova L; Zander T; Engel-Riedel W; Stoelben E; Ko YD; Randerath W; Kaminsky B; Panse J; Becker C; Hellmich M; Merkelbach-Bruse S; Heukamp LC; Büttner R; Wolf J
Oncotarget; 2015 Jan; 6(2):1315-26. PubMed ID: 25473901
[TBL] [Abstract][Full Text] [Related]
14. Multiplexed assays for detection of mutations in PIK3CA.
Board RE; Thelwell NJ; Ravetto PF; Little S; Ranson M; Dive C; Hughes A; Whitcombe D
Clin Chem; 2008 Apr; 54(4):757-60. PubMed ID: 18375489
[TBL] [Abstract][Full Text] [Related]
15. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
[TBL] [Abstract][Full Text] [Related]
16. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological characteristics and prognostic analysis of PIK3CA mutation in breast cancer patients in Northwest China.
Lv W; Du C; Zhang Y; Wu F; Jin Y; Chen X; Liu X; Feng C; Ma X; Zhang S
Pathol Res Pract; 2022 Oct; 238():154063. PubMed ID: 35994807
[TBL] [Abstract][Full Text] [Related]
19. Exon 9 Mutation of
Seo AN; Kang BW; Bae HI; Kwon OK; Park KB; Lee SS; Chung HY; Yu W; Jeon SW; Kang H; Kim JG
Anticancer Res; 2019 Apr; 39(4):2145-2154. PubMed ID: 30952761
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutation in Chinese patients with lung squamous cell carcinoma.
Yu J; Bai H; Wang Z; Wei Z; Ding X; Duan J; Yang L; Wu M; Wang Y; Wang J
Chin J Cancer Res; 2013 Aug; 25(4):416-22. PubMed ID: 23997528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]